Patents Examined by Maury Audet
  • Patent number: 10302658
    Abstract: The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but no normal tears.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: May 28, 2019
    Assignee: University of Virginia Patent Foundation
    Inventor: Gordon W. Laurie
  • Patent number: 10300109
    Abstract: Disclosed are peptidomimetic macrocycles comprising a helix, such as an alpha helix, and methods of using such macrocycles for the treatment of disease such as cancer. In other aspects, the peptidomimetic macrocycle comprises an ?,?-disubstituted amino acid, or may comprise a crosslinker linking the ?-positions of at least two amino acids or at least one of said two amino acids may be an ?,?-disubstituted amino acid. Further included is the targeting of components of the Wnt signaling pathway such as the Tcf4-/3-catenin complex.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: May 28, 2019
    Assignee: AILERON THERAPEUTICS, INC.
    Inventors: Huw M. Nash, Rosana Kapeller-Libermann, Jia-Wen Han, Tomi K. Sawyer, Justin Noehre, Noriyuki Kawahata
  • Patent number: 10300144
    Abstract: The present invention relates to a composition comprising a population of polysaccharide derivatives of a protein, wherein the protein is insulin or an insulin-like protein and the polysaccharide is anionic and comprises between 2 and 125 saccharide units, and wherein the population consists of substantially only N-terminal derivatives of the protein. Typically, the polysaccharide is PSA. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: May 28, 2019
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Rongsheng Zhang
  • Patent number: 10300108
    Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: May 28, 2019
    Assignees: Astute Medical, Inc., University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Paul McPherson, John A. Kellum
  • Patent number: 10294276
    Abstract: The present invention describes a process for isolation of romidepsin from fermentation broth and preparation of crystals of romidepsin. The process of the invention includes fewer purification steps and provides romidepsin having purity of greater than 99.5% area by HPLC. The process of the invention involves simple purification steps and hence, does not require multiple chromatographic purification steps to achieve desired quality of romidepsin. The process is advantageous over reported processes in terms of 99.5% pure yield, fast process, less expensive and less cumbersome as multiple chromatographic purification is not necessary to achieve desired quality. The process for the preparation of crystals of romidepsin provides advantages like simple steps and involves use of single solvent. The process is advantageous in terms of time, cost, and simplicity.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: May 21, 2019
    Assignee: Concord Biotech Limited
    Inventors: Ankur S. Vaid, Anand M. Dhiman, Traunkant P. Sharma
  • Patent number: 10285977
    Abstract: The present invention is directed to a composition for treating alopecia containing minoxidil, cyclosporine A and a compound that binds FK506 binding protein 4 suitable for administration to humans. The present invention is further directed to treating alopecia in humans by administering a composition of the invention.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: May 14, 2019
    Assignee: DAVID WEINSTEIN CONSULTING, INC.
    Inventor: David Weinstein
  • Patent number: 10265278
    Abstract: The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: April 23, 2019
    Inventor: Daniel Javitt
  • Patent number: 10265376
    Abstract: The inventors provide the use of a chelating agent and an antimicrobial agent that is effective against a plant pathogenic microorganism to inhibit the growth of and/or kill a plant pathogenic microorganism on a plant; the use of a chelating agent to increase the activity of an antimicrobial that is effective against a plant pathogenic microorganism; a method of inhibiting the growth of and/or killing a plant pathogenic microorganism comprising administering to a plant in need thereof a chelating agent and an antimicrobial agent that is effective against a plant pathogenic microorganism; and a method of increasing the activity of an antimicrobial that is effective against a plant pathogenic microorganism comprising using said antimicrobial with a chelating agent.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: April 23, 2019
    Assignee: Consumo Em Verde Biotecnologia Das Plantas, S.A.
    Inventors: Alexandra Manuela Lourenço Carreira, Ricardo Manuel De Seixas Boavida Ferreira, Sara Alexandra Valadas Da Silva Monteiro
  • Patent number: 10266561
    Abstract: The present subject matter is directed to a method for separating proteins of plasma using pH adjustment including the steps of reconstituting Fraction III, Fraction IV, or plasma paste, in water for injection; adjusting pH value to 1 and temperature from 1° C. to 30° C.; centrifuging the resulting suspension at 6,000 rpm at 2-8° C. for 20 min; collecting the resulting paste 1 (P1) and supernatant 1 (S1); reconstituting P1 in WFI and adjust the pH to 2; and repeating step 3) to step 5) until the pH of supernatant reaches 14. According to the method, a new formulation of immunoglobulin is prepared from plasma Fraction III and Fraction IV.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: April 23, 2019
    Inventor: Kieu Hoang
  • Patent number: 10246505
    Abstract: The present disclosure is directed to novel multispecific chimeric antigen receptor (CAR) proteins and DNA sequences encoding these proteins. The CARs comprise at least two extracellular domains fused, via a transmembrane domain to a cytoplasmic signaling domain comprising two signaling domains. The disclosure further relates to nucleic acids encoding the novel CARs, to host cells expressing the novel CARs, and to methods of using the CARs to co-stimulate effector functions in the cells and for using cells expressing the receptors for treatment of disease and viral infections. The disclosure also relates to methods of generating a recombinant T cell with reduced susceptibility to HIV infection.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: April 2, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Edward A. Berger, Mustafa H. Ghanem, Barna Dey
  • Patent number: 10239957
    Abstract: Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
  • Patent number: 10221222
    Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: March 5, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Ziqing Jiang, Robert S. Hodges, Lajos Gera, Colin T. Mant
  • Patent number: 10213487
    Abstract: The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 26, 2019
    Assignee: Eli Lilly and Company
    Inventors: Sankaram Mantripragada, Claude A. Piche, Jo Jan Filip Van Betsbrugge
  • Patent number: 10213475
    Abstract: The present invention relates to a peptide for preventing or treating inflammatory diseases and a use thereof. According to the novel dimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances and will be expected to be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: February 26, 2019
    Assignee: BIO PEP CO., LTD.
    Inventors: Dae Ho Cho, Kyung Eun Kim, Sun Young Park, Youn Kyung Houh
  • Patent number: 10213527
    Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: February 26, 2019
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Hanna Rapaport, Anna Gittelman
  • Patent number: 10206974
    Abstract: The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: February 19, 2019
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Martin Neville Shelton
  • Patent number: 10208092
    Abstract: The invention discloses kappa light chain-binding polypeptide comprising a mutated binding domain of Peptostreptococcus protein L, wherein at least one asparagine residue of a parental domain defined by, or having at least 95% or 98% sequence homology with, SEQ ID NO: 2-6 or 2 has been mutated to another amino acid residue which is not asparagine, proline or cysteine.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 19, 2019
    Assignee: GE Healthcare Bio-Process R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman
  • Patent number: 10206969
    Abstract: The present invention relates to a peptide for preventing or treating inflammatory diseases and a use thereof. According to the novel dimeric or trimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances. Therefore, it is expected that the peptide can be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: February 19, 2019
    Assignee: BIO PEP CO., LTD.
    Inventors: Dae Ho Cho, Kyung Eun Kim, Sun Young Park, Myung Jin Jung, Joo Hyun Lee
  • Patent number: 10208091
    Abstract: A kappa light chain-binding polypeptide comprising or consisting essentially of one or more binding domains of Peptostreptococcus Protein L, each of said domains being selected from the group consisting of domain 2, domain 3 and domain 4.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 19, 2019
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman
  • Patent number: 10188694
    Abstract: The present invention relates to a peptide for skin regeneration or wound healing and a use thereof. The novel peptide according to the present invention not only promotes the wound healing by increasing the production amount of collagen in dermal fibroblasts but also has an excellent whitening effect by inhibiting the production amount of melanin and tyrosinase activity of melanoma cells, and consists of peptides having a very small size to minimize side effects according to administration of external substances of very small peptides. As a result, it is expected that the novel peptide can be used as an active substance that can replace existing skin regeneration or would therapeutic agents.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: January 29, 2019
    Assignee: BIO PEP CO., LTD.
    Inventors: Dae Ho Cho, Min Chan Gil, So Mi Lee, Myun Soo Kim